Task force report: Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions

Journal of Allergy and Clinical Immunology

Volumn 109, Issue 3, 2002, Pages

  Adkinson Jr, N Franklin ^a   Essayan, David ^b   Gruchalla, Rebecca ^c   Haggerty, Helen ^d   Kawabata, Thomas ^e   Sandler, J David ^f   Updyke, Lawrence ^g   Shear, Neil H ^h   Wierda, Daniel ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d BRISTOL MYERS SQUIBB COMPANY   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^f ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h ELI LILLY AND COMPANY   (United States)

Author keywords

Adverse drug reactions; Drug allergy; Drug development; Drug hypersensitivity; Immunotoxicology

Indexed keywords

DRUG;

ARTICLE; CLINICAL PRACTICE; DIAGNOSTIC TEST; DRUG HYPERSENSITIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOTOXICITY; MEDICAL RESEARCH; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RADIOALLERGOSORBENT TEST; SKIN TEST;

EID: 0036128527     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.122214     Document Type: Article

References (83)

1. Contact sensitization: A new approach to risk assessment
2. Animal models of occupational asthma
3. An approach to allergic contact sensitization risk assessment of new chemicals and product ingredients
4. A tier approach for evaluating the respiratory allergenicity of low molecular weight chemicals
5. Drug allergy: Problems and strategies
6. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
7. Adverse drug events in hospitalized patients
8. The costs of adverse drug events in hospitalized patients
9. Concordance of the toxicity of pharmaceuticals in humans and in animals
10. T cell immune responses to haptens: Structural models for allergic and autoimmune reactions
11. T cell crossreactivity to heavy metals: Identical cryptic peptides may be presented from protein exposed to different metals
12. Role of drug hypersensitivity: A chemical, molecular, and clinical perspective
13. Recognition of sulfmethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals
14. Characterization of lidocain-specific T cells
15. Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy
16. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine
17. Drug-specific T cells derived from patients with drug-induced allergic hepatitis
18. Autoimmunity caused by xenobiotics
19. Chemical-induced autoimmunity
20. Cytochrome P-450 and drug development for skin diseases
21. Drug metabolizing enzymes in lymphocytes
22. Allergic and autoimmune reactions to xenobiotics: How do they arise?
23. Mercuric chloride alters nuclear self antigen, upregulates its presentation, and activates specific T helper cells for auto-antibody formation
24. Characterization of epitopes recognized by hapten-specific CD4+ T cells
25. Accessory molecule and costimulation requirements for CD4 T cell response
26. Tolerance, danger, and the extended family
27. Langerhans cells require signals from both tumor necrosis factor-alpha and interleukin-1 beta for migration
28. Dendritic cell accumulation in draining lymph nodes during the induction phase of contact allergy in mice
29. Non-monooygenase cytochrome P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions
30. Drug-induced autoimmune and hematologic disorders
31. Immunochemical detection and identification of protein adducts of diclofenac in the small intestine of rats: Possible role in allergic reactions
32. Genetic predisposition to drug-induced hepatotoxicity
33. Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes
34. Genetic susceptibility to toxic epidermal necrolysis
35. HLA-DR antigens and toxic reaction to sodium auruthiomate and D-penicillamine in patients with rheumatoid arthritis
36. Hydralazine-induced systemic lupus erythematosis: Influence of HLA-DR and sex on susceptibility
37. Risk factors for drug allergy
38. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock
39. Studies of the multiple drug allergy syndrome
40. Allergic reactions to antimicrobial drugs in patients with a history of prior drug allergy
41. Evidence for familial aggregation of immunologic drug reactions
42. Drug hypersensitivity reactions and human immunodeficiency virus disease
43. Allergic manifestation of human immunodeficiency virus (HIV) infection
44. Ampicillin rash in children: Relationship to penicillin allergy and infectious mononucleosis
45. Genetically determined variability in acetylation and oxidation: Therapeutic implications
46. Gender differences in adverse drug reactions
47. Skin and laboratory test in amoxicillin- and penicillin-induced morbiliform eruption
48. A diagnostic protocol for evaluating nonimmediate reactions to aminopenicillins
49. Carbamazepine and patch testing
50. Evaluation of adverse cutaneous reactions to aminopenicillins with emphasis on those manifested by maculopapular rashes
51. Phenotypic analysis of antigen-specific T lymphocytes
52. Mechanisms of adverse drug reactions
53. Opiates, mast cells and histamine release
54. Postmarketing surveillance and adverse drug reactions: Current perspective and future needs
55. Value of animal models for predicting hypersensitivity reactions to medicinal products
56. Immunotoxicology evaluation and guidelines for drug approval in Korea
57. Passive cutaneous anaphylaxis (PCA)
58. Anaphylaxis: Systemic anaphylaxis and local anaphylaxis
59. PCA reactions with mouse antibodies in mice and rats
60. The identification of contact allergen by animal assay: The guinea pig maximization test
61. A review of the Buehler guinea pig skin sensitization test and its use in a risk assessment process for human skin sensitization
62. Local lymph node assay: Use in hazard and risk assessment
63. An evaluation of guinea pig hypersensitivity test for ability to detect systemic hypersensitivity potential of drugs
64. Predictive immunotoxicological test systems: Suitability of the popliteal lymph node assay in mice and rats
65. Studies on the mechanism of drug sensitization: T-cell dependent popliteal lymph node reaction to diphenylhydantoin
66. Breaking of tolerance and MHC-dependent immune modulation by autoimmunogenic chemicals
67. The use of reporter antigens in the popliteal lymph node assay to assess immunomodulation by chemicals
68. Popliteal lymph node enlargement induced by procainamide
69. Enhanced epidermal Langerhans cell migration in IL-10 knockout mice
70. Characterization of the NZB/NZWF1 mouse model for identification of drug induced autoimmune disease
71. Halogenated anesthetics form liver adducts and antigens that cross-react with halothane-induced antibodies
72. Potential metabolic basis for enflurane hepatitis and the apparent cross-sensitization between enflurane and halothane
73. The chemical modification of proteins, haptens, and solid supports
74. Immune response to chemically modified antigens
75. Conjugated and synthetic antigens
76. An alternative strategy to the use of guinea pigs for the identification of skin sensitization hazard
77. QSAR predictive of contact allergy: Scope and limitations
78. Structure-activity relationships for skin sensitization potential: Development of structural alerts for use in knowledge-based toxicity prediction systems
79. Assessment of adverse reactions within a drug surveillance program
80. Analysis of immune-related adverse events associated with therapeutic use of drugs
81. Drug-induced anaphylaxis: A cooperative study